Lazard Capital Markets Reiterates Buy Rating for Pharmacyclics (PCYC)
Pharmacyclics (NASDAQ:PCYC)‘s stock had its “buy” rating reiterated by Lazard Capital Markets in a research note issued on Monday, American Banking and Market News reports. They currently have a $141.00 price target on the stock. Lazard Capital Markets’ target price would suggest a potential upside of 18.28% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at William Blair initiated coverage on shares of Pharmacyclics (NASDAQ:PCYC) in a research note to investors on Monday. They set an “outperform” rating on the stock. Separately, analysts at Morgan Stanley raised their price target on shares of Pharmacyclics (NASDAQ:PCYC) from $94.00 to $103.00 in a research note to investors on Monday. They now have an “equal weight” rating on the stock. Finally, analysts at Goldman Sachs Group Inc. raised their price target on shares of Pharmacyclics (NASDAQ:PCYC) from $102.00 to $111.00 in a research note to investors on Wednesday, September 18th. They now have a “buy” rating on the stock.
Five investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $118.92.
Shares of Pharmacyclics (NASDAQ:PCYC) traded down 1.28% on Monday, hitting $119.21. The stock had a trading volume of 396,910 shares. Pharmacyclics has a 52 week low of $44.91 and a 52 week high of $123.94. The stock has a 50-day moving average of $115.2 and a 200-day moving average of $93.86. The company has a market cap of $8.720 billion and a P/E ratio of 117.47.
Pharmacyclics (NASDAQ:PCYC) last released its earnings data on Wednesday, July 31st. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.33. The company had revenue of $54.70 million for the quarter, compared to the consensus estimate of $52.00 million. Analysts expect that Pharmacyclics will post $-0.16 EPS for the current fiscal year.
Pharmacyclics, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.